Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations have been reported in many cancers, including head and neck squamous cell carcinoma (HNSCC). The frequency of these mutations varies among tumor locations and might be relevant to treatment outcomes among HNSCC. In this study, we examined the frequency of PIK3CA mutations in the different subsites of HNSCC. Methods: Ninety-six fresh biopsy specimens were investigated for mutations in PIK3CA exons 4, 9, and 20 using allele-specific real-time polymerase chain reaction. Patient characteristics and survival were analyzed and compared between specimens with or without PIK3CA mutations. Results: The study included primary tumors originating from the oral cavity (n = 63), hypopharynx (n = 23), and oropharynx (n = 10). We identified mutations in 10.4% of patients (10 of 96 specimens). The overall mutational frequency was 17.4% (4/23) and 9.5% (6/63) in the hypopharynx and oral cavity, respectively. No patients with oropharyngeal carcinoma had mutations. Among the 10 mutant specimens, five were missense mutations (exon 9 [E545K] in two samples and exon 20 [H1047R] in three samples) and five were silent mutations in exon 20 (T1025T). Mutations were not found in exon 4. Among 84 patients with available clinical data, we found no significant differences in clinical characteristics and survival based on the presence or absence of PIK3CA mutations. Conclusions: The results indicate that PIK3CA mutations are involved in HNSCC carcinogenesis, and the hypopharynx should be considered a primary site of interest for future studies, particularly in Southeast Asian populations.
Abstract
Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations have been reported in many cancers, including head and neck squamous cell carcinoma (HNSCC). The frequency of these mutations varies among tumor locations and might be relevant to treatment outcomes among HNSCC. In this study, we examined the frequency of PIK3CA mutations in the different subsites of HNSCC. Methods: Ninety-six fresh biopsy specimens were investigated for mutations in PIK3CA exons 4, 9, and 20 using allele-specific real-time polymerase chain reaction. Patient characteristics and survival were analyzed and compared between specimens with or without PIK3CA mutations. Results: The study included primary tumors originating from the oral cavity (n = 63), hypopharynx (n = 23), and oropharynx (n = 10). We identified mutations in 10.4% of patients (10 of 96 specimens). The overall mutational frequency was 17.4% (4/23) and 9.5% (6/63) in the hypopharynx and oral cavity, respectively. No patients with oropharyngeal carcinoma had mutations. Among the 10 mutant specimens, five were missense mutations (exon 9 [E545K] in two samples and exon 20 [H1047R] in three samples) and five were silent mutations in exon 20 (T1025T). Mutations were not found in exon 4. Among 84 patients with available clinical data, we found no significant differences in clinical characteristics and survival based on the presence or absence of PIK3CA mutations. Conclusions: The results indicate that PIK3CA mutations are involved in HNSCC carcinogenesis, and the hypopharynx should be considered a primary site of interest for future studies, particularly in Southeast Asian populations.
참고문헌 (32)
- Cohen N, "Epidemiology and demographics of the head and neck cancer population", Oral Maxillofac Surg Clin North Am, 30, pp.381~395 (2018)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- "Hospital-based cancer registry 2016"[URL]
- Cancer Genome Atlas Network, "Comprehensive genomic characterization of head and neck squamous cell carcinomas", Nature, 517, pp.576~582 (2015)
- Wang Z, "mTOR co-targeting strategies for head and neck cancer therapy", Cancer Metastasis Rev, 36, pp.491~502 (2017)
- Liu P, "Targeting the phosphoinositide 3-kinase pathway in cancer", Nat Rev Drug Discov, 8, pp.627~644 (2009)
- Karakas B, "Mutation of the PIK3CA oncogene in human cancers", Br J Cancer, 94, pp.455~459 (2006)
- Qiu W, "PIK3CA mutations in head and neck squamous cell carcinoma", Clin Cancer Res, 12, pp.1441~1446 (2006)
- Kozaki K, "PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma", Cancer Sci, 97, pp.1351~1358 (2006)
- Or YY, "PIK3CA mutations in nasopharyngeal carcinoma", Int J Cancer, 118, pp.1065~1067 (2006)
- Qiu W, "Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer", Int J Cancer, 122, pp.1189~1194 (2008)
- Murugan AK, "Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas", Int J Oncol, 32, pp.101~111 (2008)
- Chou CC, "PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival", Med Oncol, 26, pp.322~326 (2009)
- Fendri A, "PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma", Cancer Sci, 100, pp.2034~2039 (2009)
- Kommineni N, "Association of PIK3CA gene mutations with head and neck squamous cell carcinomas", Neoplasma, 62, pp.72~80 (2015)
- Wu P, "Whole-exome sequencing reveals novel mutations and epigenetic regulation in hypopharyngeal carcinoma", Oncotarget, 8, pp.85326~85340 (2017)
- Nichols AC, "High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer", JAMA Otolaryngol Head Neck Surg, 139, pp.617~622 (2013)
- Beaty BT, "PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation", J Natl Cancer Inst, 112, pp.855~858 (2020)
- Arsa L, "Discrepancy in p16 expression in patients with HPV-associated head and neck squamous cell carcinoma in Thailand : clinical characteristics and survival outcomes", BMC Cancer, 21, pp.504~ (2021)
- Argirion I, "Increasing prevalence of HPV in oropharyngeal carcinoma suggests adaptation of p16 screening in Southeast Asia", J Clin Virol, 132, pp.104637~ (2020)
- Mehanna H, "Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer : systematic review and meta-analysis of trends by time and region", Head Neck, 35, pp.747~755 (2013)
- Samuels Y, "High frequency of mutations of the PIK3CA gene in human cancers", Science, 304, pp.554~ (2004)
- Kang S, "Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic", Proc Natl Acad Sci U S A, 102, pp.802~807 (2005)
- Davoli T, "Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover", Genes Dev, 30, pp.2684~2695 (2016)
- Gustin JP, "The PIK3CA gene as a mutated target for cancer therapy", Curr Cancer Drug Targets, 8, pp.733~740 (2008)
- Miled N, "Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit", Science, 317, pp.239~242 (2007)
- Kang S, "Mutated PI 3-kinases : cancer targets on a silver platter", Cell Cycle, 4, pp.578~581 (2005)
- Dogruluk T, "Identification of variantspecific functions of PIK3CA by rapid phenotyping of rare mutations", Cancer Res, 75, pp.5341~5354 (2015)
- Andre F, "Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer", N Engl J Med, 380, pp.1929~1940 (2019)
- Andre F, "Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer : final overall survival results from SOLAR-1", Ann Oncol, 32, pp.208~217 (2021)
- Jung K, "Targeting phosphoinositide 3-kinase(PI3K)in head and neck squamous cell carcinoma(HNSCC)", Cancers Head Neck, 3, pp.3~ (2018)
- Lui VW, "Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers", Cancer Discov, 3, pp.761~769 (2013)